PHF6 and acute lymphoblastic leukemia: Interestingly, PHF6 mutation rates are significantly lower in B-ALL and AML patients when compared with that of T-ALL patients [24, 35], and in contrast to its role in T-ALL, PHF6 appears to play a pro-oncogenic role in B-ALL and AML.